Why Farbe Firma is the Top Manufacturer of Metoprolol Tartrate Injection
- Maulik Sudani
- 6 hours ago
- 7 min read
Last Updated: June 18, 2026
TL;DR: Metoprolol Tartrate Injection — a sterile, clear, colourless aqueous solution of metoprolol tartrate, a cardioselective beta-1 adrenergic blocker, supplied commonly as a 1 mg/mL solution in a 5 mg/5 mL ampoule or vial for slow intravenous bolus — is a frontline hospital agent for the early management of acute myocardial infarction and for the acute control of supraventricular tachyarrhythmias and rapid heart rate. Because the patient is often acutely unstable and the drug is given as a slow, titrated intravenous bolus under cardiac monitoring, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled concentration, with the assay, the impurity and degradation profile, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Metoprolol Tartrate Injection at our Gujarat, India facility and supplies it to emergency, cardiology, intensive-care and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Cardioselective beta-1 adrenergic blocker (metoprolol tartrate) — Metoprolol Tartrate Injection is given as a slow, titrated intravenous bolus under continuous cardiac monitoring for the early treatment of acute myocardial infarction and for the acute control of supraventricular tachyarrhythmias and rapid ventricular rate, where precise, reproducible dosing is essential.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated compounding and ampoule/vial filling lines, control of the stability-indicating assay, the impurity and degradation profile, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Metoprolol Tartrate Injection Demands a Premium Manufacturer
Metoprolol Tartrate Injection holds a critical, time-sensitive place in emergency departments, cardiology services and intensive-care units across every market. It is the intravenous beta-blocker that clinicians reach for in the early hours of an acute myocardial infarction and for bringing a dangerously fast supraventricular tachyarrhythmia under control, where slowing the heart and reducing its workload quickly and predictably can protect the myocardium and stabilise the patient. As a cardioselective beta-1 adrenergic blocker given as a slow, titrated bolus under continuous monitoring, metoprolol lets a treating team adjust heart rate and rhythm in real time. In each of these settings the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, because safe titration in an unstable cardiac patient depends on a precise, reproducible dose given without delay.
That clinical reality places real demands on the manufacturer. Metoprolol Tartrate Injection is a low-strength, clear aqueous solution — commonly 1 mg/mL in a 5 mg/5 mL presentation — given directly into the bloodstream, so the assay must be exact at low concentration, the impurity and degradation profile must stay within tight limits, the solution pH must be controlled to the range that keeps the molecule stable, the solution must be isotonic and the fill volume accurate so each ampoule delivers the labelled dose, and the product must be free of visible and sub-visible particulates and low in endotoxin. Because it is a simple, relatively heat-tolerant small-molecule solution, the manufacturer must select and validate the right sterilisation route — terminal moist-heat sterilisation where the formulation and container qualify, otherwise full aseptic processing — and protect the assay and clarity across shelf life. Choosing a Metoprolol Tartrate Injection manufacturer that treats the stability-indicating assay, pH and tonicity control, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Metoprolol Tartrate Injection Manufacturer Apart
A world-class manufacturer of Metoprolol Tartrate Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of metoprolol tartrate with related-substance and degradation control by validated HPLC — accurate even at the low 1 mg/mL strength — that an acute cardiac medicine demands, a robust, validated sterilisation and fill process that protects sterility, pH and clarity in a low-strength aqueous solution, and tender-ready dossier support for a high-volume hospital-formulary cardiovascular product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade metoprolol tartrate sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay and the pH of a low-strength solution. The bulk solution is compounded in water-for-injection with the tonicity adjustment and at the controlled pH that keeps metoprolol tartrate stable, sterile-filtered through 0.22 µm membrane, and filled into ampoules or vials under ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of metoprolol tartrate by validated HPLC, the related-substance and degradation profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intravenous administration. Because the strength is low and the medicine is given by direct intravenous bolus, assay accuracy, pH control and container-closure integrity are validated together so the assay and clarity stay within specification across shelf life.
Quality Systems Behind Every Metoprolol Tartrate Injection
Every Farbe Firma Metoprolol Tartrate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of metoprolol tartrate against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because metoprolol tartrate injection is a low-strength intravenous cardiac medicine and the assay, pH, particulate and endotoxin burden drive both efficacy and safety, we treat the stability-indicating assay, the solution pH, the deliverable volume and the particulate burden as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, so the assay, clarity and pH stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Metoprolol Tartrate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad emergency, cardiology and critical-care small-volume parenteral portfolio. For Metoprolol Tartrate Injection specifically, we supply the 1 mg/mL solution in the 5 mg/5 mL ampoule and vial presentation under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, impurity, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Metoprolol Tartrate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development at low strength, related-substance and degradation control, pH and tonicity formulation design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For an acute cardiovascular medicine where assay accuracy, pH control, fill-volume accuracy and particulate control directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Metoprolol Tartrate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Metoprolol Tartrate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated compounding and ampoule/vial filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Metoprolol Tartrate Injection do you supply?
Our standard presentation is the 1 mg/mL solution of metoprolol tartrate in a 5 mg/5 mL ampoule or vial, for slow intravenous bolus. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Metoprolol Tartrate Injection mainly used for?
Metoprolol Tartrate Injection is used for the early treatment of acute myocardial infarction and for the acute control of supraventricular tachyarrhythmias and rapid heart rate. It is a cardioselective beta-1 adrenergic blocker given as a slow, titrated intravenous bolus under cardiac monitoring; Farbe Firma verifies the assay, pH, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Metoprolol Tartrate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Metoprolol Tartrate Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our acute cardiovascular small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments